Drug Type Small molecule drug |
Synonyms Batenac, Befral, Cerate + [12] |
Target |
Mechanism T-type calcium channel activators(Voltage-gated T-type calcium channel activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (20 Jun 1997), |
RegulationOrphan Drug (US) |
Molecular FormulaC29H40Cl2FN3O3 |
InChIKeyMTJLQTFHJIHXIX-GDUXWEAWSA-N |
CAS Registry116666-63-8 |
Indication | Highest Phase | Country/Location | Organization |
---|---|---|---|
Angina, Stable | Withdrawn | US More | Roche Holding AG More |
Hypertension | Withdrawn | US More | Roche Holding AG More |
Pancreatic Cancer | Pending | US More | Cavion, Inc. More |
Ovarian Cancer | Pending | US More | Cavion, Inc. More |
Glioma | Pending | US More | Cavion, Inc. More |
Phase 1 | 27 | (gkgjeqjfzg) = stheznhihs fpkmcfksjf (wdkuobsiji ) View more | - | 20 May 2015 | |||
Phase 1 | 18 | Mibefradil dihydrochloride + hypofractionated radiation | (zmfhigdxod) = wfudfbsfty odkpueqmyy (lechhyjdik ) View more | Positive | 01 Jun 2018 | ||
Not Applicable | - | (tptdgaxdbl) = vhbxszbdtz ucmvormdmc (uhkrpbjihh ) | - | 15 Apr 2012 | |||
Phase 1 | 28 | (stxakphnbi) = xmawebqcwe hsjllzccyx (eifvjxebip ) | - | 01 Jun 2017 |